Engineering Therapeutic Cancer Vaccines That Activate Antitumor Immunity

  • Per Ole Iversen
  • Mouldy Sioud
Part of the Methods in Molecular Biology book series (MIMB, volume 1218)


Vaccination represents one the most effective methods of preventing disease. Because dendritic cells (DCs) are the most efficient antigen presenting cells, exploiting their plasticity is likely to yield improved therapeutic vaccines. Herein, we applied a novel DC-based vaccine (i.e., DC loaded with leukemia antigens that have been transfected with an IL-10 siRNA capable of coordinately activating DCs via TLR7/8) in a rat model of acute myeloid leukemia. Leukemic rats treated with this new vaccine had less leukemic cell mass in their bone marrows and less extramedullar dissemination of the leukemic disease examined postmortem compared with rats given the control vaccine. Collectively, the new strategy demonstrates the possible usefulness of dual siRNAs as an immunomodulatory drug with antileukemic properties.

Key words

Dendritic cells siRNA Leukemia Immunotherapy 


  1. 1.
    Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J et al (2003) Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 987:180–187PubMedCrossRefGoogle Scholar
  2. 2.
    Blander JM, Medzhitov R (2006) On regulation of phagosome maturation and antigen presentation. Nat Immunol 7:1029–1035PubMedCrossRefGoogle Scholar
  3. 3.
    Sioud M (2006) Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med 12:167–176PubMedCrossRefGoogle Scholar
  4. 4.
    Kabelitz D, Wesch D, Oberg HH (2006) Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 26:291–306PubMedCrossRefGoogle Scholar
  5. 5.
    Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811Google Scholar
  6. 6.
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498PubMedCrossRefGoogle Scholar
  7. 7.
    Sioud M (2004) Therapeutic siRNAs. Trends Pharmacol Sci 25:22–28PubMedCrossRefGoogle Scholar
  8. 8.
    Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348:1079–1090PubMedCrossRefGoogle Scholar
  9. 9.
    Furset G, Sioud M (2007) Design of bifunctional siRNAs: combining immuno-stimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 352:642–649PubMedCrossRefGoogle Scholar
  10. 10.
    Iversen PO, Semaeva E, Sørensen DR, Wiig H, Sioud M (2009) Dendritic cells loaded with tumor antigens and a dual immunostimulatory and anti-interleukin 10-specific small interference RNA prime T lymphocytes against leukemic cells. Transl Oncol 2:242–246PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Sioud M (2006) Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol 36:1222–1230PubMedCrossRefGoogle Scholar
  12. 12.
    Sioud M, Furset G, Cekaite L (2007) Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun 361:122–126PubMedCrossRefGoogle Scholar
  13. 13.
    Martens AC, van Bekkum DW, Hagenbeek A (1990) The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)). Leukemia 4:241–257PubMedGoogle Scholar
  14. 14.
    Iversen PO, Sørensen DR, Tronstad KJ, Gudbrandsen OA, Rustan AC, Berge RK, Drevon CA (2006) A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clin Cancer Res 12:3525–3531PubMedCrossRefGoogle Scholar
  15. 15.
    Martens AC, Johnson RJ, Kaizer H, Hagenbeek A (1984) Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells. Exp Hematol 2:667–671Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of NutritionOslo University Hospital, NorwayMontebelloNorway
  2. 2.Department of ImmunologyOslo University Hospital, NorwayMontebelloNorway
  3. 3.Department of Immunology, Institute for Cancer ResearchThe Norwegian Radium HospitalMontebelloNorway

Personalised recommendations